Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

J M Kirkwood, M H Strawderman, Marc S. Ernstoff et al. · Journal of Clinical Oncology · 1996 · 2.1K citations

Medicine, Oncology, Pharmacotherapy +17

Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2

Steven A. Rosenberg · JAMA · 1994 · 1.1K citations

Medicine, Immunology, Oncology +11

Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

Jon Richards, Natasha Mehta, Kathy Ramming et al. · Journal of Clinical Oncology · 1992 · 257 citations

Medicine, Clinical Sciences, Oncology +17

Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.

Salvatore A. Del Prete, L. Herbert Maurer, J O'Donnell et al. · PubMed · 1984 · 230 citations

Medicine, Oncology, Pharmacology +13

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

Ulrich Keilholz, S.H. Goey, Cornelis J.A. Punt et al. · Journal of Clinical Oncology · 1997 · 196 citations

Pharmacy, Oncology, Pharmacotherapy +15